B-control	0	3	Six
O	4	10	versus
B-intervention	11	13	12
I-intervention	14	20	months
I-intervention	21	23	of
I-intervention	24	32	adjuvant
I-intervention	33	44	trastuzumab
I-intervention	45	47	in
I-intervention	48	59	combination
I-intervention	60	64	with
I-intervention	65	69	dose
I-intervention	69	70	-
I-intervention	70	75	dense
I-intervention	76	88	chemotherapy
O	89	92	for
O	93	98	women
O	99	103	with
O	104	108	HER2
O	108	109	-
O	109	117	positive
O	118	124	breast
O	125	131	cancer
O	131	132	:
O	133	134	a
O	135	146	multicenter
O	147	157	randomized
O	158	163	study
O	164	166	by
O	167	170	the
O	171	179	Hellenic
O	180	188	Oncology
O	189	197	Research
O	198	203	Group
O	204	205	(
O	205	209	HORG
O	209	210	)
O	210	211	.

O	212	220	Adjuvant
O	221	232	trastuzumab
O	233	235	in
O	236	247	combination
O	248	252	with
O	253	265	chemotherapy
O	266	274	improves
O	275	283	survival
O	284	286	of
O	287	292	women
O	293	297	with
O	298	302	HER2
O	302	303	-
O	303	311	positive
O	312	317	early
O	318	324	breast
O	325	331	cancer
O	331	332	.

O	333	335	In
O	336	340	this
O	341	346	study
O	346	347	,
O	348	350	we
O	351	359	compared
O	360	362	12
O	363	369	versus
O	370	371	6
O	372	378	months
O	379	381	of
O	382	390	adjuvant
O	391	402	trastuzumab
O	402	403	.

B-eligibility	404	412	Axillary
I-eligibility	413	417	node
I-eligibility	417	418	-
I-eligibility	418	426	positive
I-eligibility	427	429	or
I-eligibility	430	434	high
I-eligibility	434	435	-
I-eligibility	435	439	risk
I-eligibility	440	444	node
I-eligibility	444	445	-
I-eligibility	445	453	negative
I-eligibility	454	459	women
I-eligibility	460	464	with
I-eligibility	465	469	HER2
I-eligibility	469	470	-
I-eligibility	470	478	positive
I-eligibility	479	484	early
I-eligibility	485	491	breast
I-eligibility	492	498	cancer
O	499	503	were
O	504	514	randomized
O	515	517	to
O	518	525	receive
O	526	528	12
O	529	531	or
O	532	533	6
O	534	540	months
O	541	543	of
O	544	552	adjuvant
O	553	564	trastuzumab
O	565	577	concurrently
O	578	582	with
O	583	587	dose
O	587	588	-
O	588	593	dense
O	593	594	,
O	595	606	granulocyte
O	607	613	colony
O	613	614	-
O	614	625	stimulating
O	626	632	factor
O	633	634	(
O	634	635	G
O	635	636	-
O	636	639	CSF
O	639	640	)
O	640	641	-
O	641	650	supported
O	651	660	docetaxel
O	661	662	(
O	662	664	75
O	665	667	mg
O	667	668	/
O	668	669	m
O	669	670	(
O	670	671	2
O	671	672	)
O	673	678	every
O	679	681	14
O	682	686	days
O	687	690	for
O	691	695	four
O	696	702	cycles
O	702	703	)
O	703	704	.

O	705	708	All
O	709	717	patients
O	718	726	received
O	727	734	upfront
O	735	739	dose
O	739	740	-
O	740	745	dense
O	745	746	,
O	747	748	G
O	748	749	-
O	749	752	CSF
O	752	753	-
O	753	762	supported
O	763	766	FEC
O	767	768	(
O	768	769	5
O	769	770	-
O	770	782	fluorouracil
O	783	786	700
O	787	789	mg
O	789	790	/
O	790	791	m
O	791	792	(
O	792	793	2
O	793	794	)
O	794	795	,
O	796	806	epirubicin
O	807	809	75
O	810	812	mg
O	812	813	/
O	813	814	m
O	814	815	(
O	815	816	2
O	816	817	)
O	817	818	,
O	819	835	cyclophosphamide
O	836	839	700
O	840	842	mg
O	842	843	/
O	843	844	m
O	844	845	(
O	845	846	2
O	846	847	)
O	848	853	every
O	854	856	14
O	857	861	days
O	862	865	for
O	866	870	four
O	871	877	cycles
O	877	878	)
O	878	879	.

O	880	893	Randomization
O	894	897	was
O	898	905	carried
O	906	909	out
O	910	916	before
O	917	925	commence
O	926	928	of
O	929	941	chemotherapy
O	941	942	.

O	943	946	The
O	947	954	primary
O	955	958	end
O	959	964	point
O	965	968	was
O	969	972	the
B-outcome-Measure	973	974	3
I-outcome-Measure	974	975	-
I-outcome-Measure	975	979	year
I-outcome-Measure	980	987	disease
I-outcome-Measure	987	988	-
I-outcome-Measure	988	992	free
I-outcome-Measure	993	1001	survival
I-outcome-Measure	1002	1003	(
I-outcome-Measure	1003	1006	DFS
I-outcome-Measure	1006	1007	)
O	1007	1008	.

O	1009	1010	A
O	1011	1016	total
O	1017	1019	of
B-total-participants	1020	1023	481
O	1024	1032	patients
O	1033	1037	were
O	1038	1048	randomized
O	1049	1051	to
O	1052	1059	receive
O	1060	1062	12
O	1063	1069	months
O	1070	1071	(
O	1071	1072	n
O	1073	1074	=
B-intervention-participants	1075	1078	241
O	1078	1079	)
O	1080	1082	or
O	1083	1084	6
O	1085	1091	months
O	1092	1093	(
O	1093	1094	n
O	1095	1096	=
B-control-participants	1097	1100	240
O	1100	1101	)
O	1102	1104	of
O	1105	1113	adjuvant
O	1114	1125	trastuzumab
O	1125	1126	.

O	1127	1139	Chemotherapy
O	1140	1143	was
O	1144	1153	completed
O	1154	1156	in
O	1157	1159	99
O	1159	1160	%
O	1161	1164	and
O	1165	1167	98
O	1167	1168	%
O	1169	1171	of
O	1172	1180	patients
O	1180	1181	,
O	1182	1187	while
O	1188	1199	trastuzumab
O	1200	1207	therapy
O	1208	1210	in
O	1211	1214	100
O	1214	1215	%
O	1216	1219	and
O	1220	1222	96
O	1222	1223	%
O	1224	1226	of
O	1227	1235	patients
O	1236	1238	in
O	1239	1242	the
O	1243	1245	12
O	1245	1246	-
O	1247	1250	and
O	1251	1252	6
O	1252	1253	-
O	1253	1258	month
O	1259	1265	groups
O	1265	1266	,
O	1267	1279	respectively
O	1279	1280	.

O	1281	1286	After
O	1287	1289	47
O	1290	1293	and
O	1294	1296	51
O	1297	1303	months
O	1304	1306	of
O	1307	1313	median
O	1314	1320	follow
O	1320	1321	-
O	1321	1323	up
O	1323	1324	,
O	1325	1330	there
O	1331	1335	were
B-iv-bin-abs	1336	1338	17
O	1339	1340	(
B-iv-bin-percent	1340	1341	7
I-iv-bin-percent	1341	1342	.
I-iv-bin-percent	1342	1343	1
I-iv-bin-percent	1343	1344	%
O	1344	1345	)
O	1346	1349	and
B-cv-bin-abs	1350	1352	28
O	1353	1354	(
B-cv-bin-percent	1354	1356	11
I-cv-bin-percent	1356	1357	.
I-cv-bin-percent	1357	1358	7
I-cv-bin-percent	1358	1359	%
O	1359	1360	)
B-outcome	1361	1368	disease
I-outcome	1369	1377	relapses
O	1378	1380	in
O	1381	1384	the
O	1385	1387	12
O	1387	1388	-
O	1389	1392	and
O	1393	1394	6
O	1394	1395	-
O	1395	1400	month
O	1401	1407	groups
O	1408	1409	(
O	1409	1410	P
O	1411	1412	=
O	1413	1414	0
O	1414	1415	.
O	1415	1417	08
O	1417	1418	)
O	1418	1419	.

O	1420	1423	The
B-outcome	1424	1425	3
I-outcome	1425	1426	-
I-outcome	1426	1430	year
I-outcome	1431	1434	DFS
O	1435	1438	was
B-iv-bin-percent	1439	1441	95
I-iv-bin-percent	1441	1442	.
I-iv-bin-percent	1442	1443	7
I-iv-bin-percent	1443	1444	%
O	1445	1451	versus
B-cv-bin-percent	1452	1454	93
I-cv-bin-percent	1454	1455	.
I-cv-bin-percent	1455	1456	3
I-cv-bin-percent	1456	1457	%
O	1458	1460	in
O	1461	1466	favor
O	1467	1469	of
O	1470	1473	the
O	1474	1476	12
O	1476	1477	-
O	1477	1482	month
O	1483	1492	treatment
O	1493	1498	group
O	1499	1500	(
O	1500	1506	hazard
O	1507	1512	ratio
O	1513	1514	=
O	1515	1516	1
O	1516	1517	.
O	1517	1519	57
O	1519	1520	;
O	1521	1523	95
O	1523	1524	%
O	1525	1535	confidence
O	1536	1544	interval
O	1545	1546	0
O	1546	1547	.
O	1547	1549	86
O	1549	1550	-
O	1550	1551	2
O	1551	1552	.
O	1552	1554	10
O	1554	1555	;
O	1556	1557	P
O	1558	1559	=
O	1560	1561	0
O	1561	1562	.
O	1562	1565	137
O	1565	1566	)
O	1566	1567	.

O	1568	1573	There
O	1574	1577	was
O	1578	1580	no
O	1581	1591	difference
O	1592	1594	in
O	1595	1600	terms
O	1601	1603	of
B-outcome	1604	1611	overall
I-outcome	1612	1620	survival
O	1621	1624	and
B-outcome	1625	1632	cardiac
I-outcome	1633	1641	toxicity
O	1642	1649	between
O	1650	1653	the
O	1654	1657	two
O	1658	1664	groups
O	1664	1665	.

O	1666	1669	Our
O	1670	1675	study
O	1676	1682	failed
O	1683	1685	to
O	1686	1690	show
O	1691	1705	noninferiority
O	1706	1709	for
O	1710	1713	the
O	1714	1715	6
O	1715	1716	-
O	1716	1721	month
O	1722	1725	arm
O	1725	1726	.

O	1727	1730	The
O	1731	1738	results
O	1739	1746	further
O	1747	1754	support
O	1755	1758	the
O	1759	1766	current
O	1767	1775	standard
O	1776	1778	of
O	1779	1783	care
O	1784	1788	that
O	1789	1791	is
O	1792	1806	administration
O	1807	1809	of
O	1810	1818	adjuvant
O	1819	1830	trastuzumab
O	1831	1834	for
O	1835	1837	12
O	1838	1844	months
O	1844	1845	.
